NVIDIA vs Broadcom Stock: Which Is Best?
If you want to invest in an AI-leading tech company,…
Sell
41
NMTC Quote, Financials, Valuation and Earnings
Last price:
$0.76
Seasonality move
:
66.87%
Day range:
$0.73 - $0.77
52-week range:
$0.55 - $1.72
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
5.88x
P/B ratio:
28.45x
Volume:
100K
Avg. volume:
238.9K
1-year change:
-45.06%
Market cap:
$23.4M
Revenue:
$3.5M
EPS (TTM):
-$0.46
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
NMTC
NeuroOne Medical Technologies
|
-- | -- | 157.41% | -57.14% | -- |
|
CVRX
CVRx
|
$13.2M | -$0.47 | 34.46% | -11.77% | -- |
|
NTRB
Nutriband
|
-- | -- | -- | -- | -- |
|
NVNO
enVVeno Medical
|
-- | -$0.33 | -- | -26.67% | -- |
|
SINT
SINTX Technologies
|
$700K | -$5.29 | 20.07% | -96.58% | -- |
|
XAIR
Beyond Air
|
$1M | -- | 138.36% | -- | -- |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
NMTC
NeuroOne Medical Technologies
|
$0.76 | -- | $23.4M | -- | $0.00 | 0% | 5.88x |
|
CVRX
CVRx
|
$12.11 | -- | $293.8M | -- | $0.00 | 0% | 5.54x |
|
NTRB
Nutriband
|
$4.05 | -- | $45M | -- | $0.00 | 0% | 19.85x |
|
NVNO
enVVeno Medical
|
$2.50 | -- | $43.9M | -- | $0.00 | 0% | 213.30x |
|
SINT
SINTX Technologies
|
$3.52 | -- | $4.7M | -- | $0.00 | 0% | 0.96x |
|
XAIR
Beyond Air
|
$0.41 | -- | $29.6M | -- | $0.00 | 0% | 7.10x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
NMTC
NeuroOne Medical Technologies
|
-- | -1.235 | -- | 0.74x |
|
CVRX
CVRx
|
43.02% | 0.327 | 23.08% | 9.97x |
|
NTRB
Nutriband
|
1.68% | 2.279 | 0.28% | 4.65x |
|
NVNO
enVVeno Medical
|
-- | 2.437 | -- | -- |
|
SINT
SINTX Technologies
|
2.35% | 0.698 | 3.06% | 2.48x |
|
XAIR
Beyond Air
|
28.48% | 1.673 | 38.38% | 4.46x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
NMTC
NeuroOne Medical Technologies
|
$141.1K | -$2.8M | -335.54% | -335.54% | -1108.64% | -$2.7M |
|
CVRX
CVRx
|
$11.1M | -$13M | -58.86% | -84.64% | -90.44% | -$10.4M |
|
NTRB
Nutriband
|
$191K | -$1.4M | -65.19% | -69.58% | -210.38% | -$1.1M |
|
NVNO
enVVeno Medical
|
-- | -$6.2M | -- | -- | -- | -$4.3M |
|
SINT
SINTX Technologies
|
$157K | -$2M | -130.78% | -132.95% | -1697.55% | -$2.6M |
|
XAIR
Beyond Air
|
-$1.1M | -$12.8M | -140.46% | -219.34% | -1641.86% | -$14.5M |
NeuroOne Medical Technologies vs. Competitors
-
Which has Higher Returns NMTC or CVRX?
CVRx has a net margin of -1230.55% compared to NeuroOne Medical Technologies's net margin of -97.95%. NeuroOne Medical Technologies's return on equity of -335.54% beat CVRx's return on equity of -84.64%.
Company Gross Margin Earnings Per Share Invested Capital NMTCNeuroOne Medical Technologies51.81% -$0.11 $822K CVRXCVRx83.19% -$0.57 $114.4M -
What do Analysts Say About NMTC or CVRX?
NeuroOne Medical Technologies has a consensus price target of --, signalling upside risk potential of 163.78%. On the other hand CVRx has an analysts' consensus of -- which suggests that it could grow by 50.01%. Given that NeuroOne Medical Technologies has higher upside potential than CVRx, analysts believe NeuroOne Medical Technologies is more attractive than CVRx.
Company Buy Ratings Hold Ratings Sell Ratings NMTCNeuroOne Medical Technologies0 0 0 CVRXCVRx0 0 0 -
Is NMTC or CVRX More Risky?
NeuroOne Medical Technologies has a beta of 0.688, which suggesting that the stock is 31.224% less volatile than S&P 500. In comparison CVRx has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock NMTC or CVRX?
NeuroOne Medical Technologies has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. CVRx offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. NeuroOne Medical Technologies pays -- of its earnings as a dividend. CVRx pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios NMTC or CVRX?
NeuroOne Medical Technologies quarterly revenues are $272.3K, which are smaller than CVRx quarterly revenues of $13.4M. NeuroOne Medical Technologies's net income of -$3.4M is higher than CVRx's net income of -$13.1M. Notably, NeuroOne Medical Technologies's price-to-earnings ratio is -- while CVRx's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for NeuroOne Medical Technologies is 5.88x versus 5.54x for CVRx. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income NMTCNeuroOne Medical Technologies5.88x -- $272.3K -$3.4M CVRXCVRx5.54x -- $13.4M -$13.1M
-
Which has Higher Returns NMTC or NTRB?
Nutriband has a net margin of -1230.55% compared to NeuroOne Medical Technologies's net margin of -211%. NeuroOne Medical Technologies's return on equity of -335.54% beat Nutriband's return on equity of -69.58%.
Company Gross Margin Earnings Per Share Invested Capital NMTCNeuroOne Medical Technologies51.81% -$0.11 $822K NTRBNutriband29.58% -$0.12 $11.4M -
What do Analysts Say About NMTC or NTRB?
NeuroOne Medical Technologies has a consensus price target of --, signalling upside risk potential of 163.78%. On the other hand Nutriband has an analysts' consensus of -- which suggests that it could grow by 344.44%. Given that Nutriband has higher upside potential than NeuroOne Medical Technologies, analysts believe Nutriband is more attractive than NeuroOne Medical Technologies.
Company Buy Ratings Hold Ratings Sell Ratings NMTCNeuroOne Medical Technologies0 0 0 NTRBNutriband0 0 0 -
Is NMTC or NTRB More Risky?
NeuroOne Medical Technologies has a beta of 0.688, which suggesting that the stock is 31.224% less volatile than S&P 500. In comparison Nutriband has a beta of 0.358, suggesting its less volatile than the S&P 500 by 64.193%.
-
Which is a Better Dividend Stock NMTC or NTRB?
NeuroOne Medical Technologies has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Nutriband offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. NeuroOne Medical Technologies pays -- of its earnings as a dividend. Nutriband pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios NMTC or NTRB?
NeuroOne Medical Technologies quarterly revenues are $272.3K, which are smaller than Nutriband quarterly revenues of $645.8K. NeuroOne Medical Technologies's net income of -$3.4M is lower than Nutriband's net income of -$1.4M. Notably, NeuroOne Medical Technologies's price-to-earnings ratio is -- while Nutriband's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for NeuroOne Medical Technologies is 5.88x versus 19.85x for Nutriband. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income NMTCNeuroOne Medical Technologies5.88x -- $272.3K -$3.4M NTRBNutriband19.85x -- $645.8K -$1.4M
-
Which has Higher Returns NMTC or NVNO?
enVVeno Medical has a net margin of -1230.55% compared to NeuroOne Medical Technologies's net margin of --. NeuroOne Medical Technologies's return on equity of -335.54% beat enVVeno Medical's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital NMTCNeuroOne Medical Technologies51.81% -$0.11 $822K NVNOenVVeno Medical-- -$0.35 -- -
What do Analysts Say About NMTC or NVNO?
NeuroOne Medical Technologies has a consensus price target of --, signalling upside risk potential of 163.78%. On the other hand enVVeno Medical has an analysts' consensus of -- which suggests that it could grow by 619.71%. Given that enVVeno Medical has higher upside potential than NeuroOne Medical Technologies, analysts believe enVVeno Medical is more attractive than NeuroOne Medical Technologies.
Company Buy Ratings Hold Ratings Sell Ratings NMTCNeuroOne Medical Technologies0 0 0 NVNOenVVeno Medical0 0 0 -
Is NMTC or NVNO More Risky?
NeuroOne Medical Technologies has a beta of 0.688, which suggesting that the stock is 31.224% less volatile than S&P 500. In comparison enVVeno Medical has a beta of 1.219, suggesting its more volatile than the S&P 500 by 21.904%.
-
Which is a Better Dividend Stock NMTC or NVNO?
NeuroOne Medical Technologies has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. enVVeno Medical offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. NeuroOne Medical Technologies pays -- of its earnings as a dividend. enVVeno Medical pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios NMTC or NVNO?
NeuroOne Medical Technologies quarterly revenues are $272.3K, which are larger than enVVeno Medical quarterly revenues of --. NeuroOne Medical Technologies's net income of -$3.4M is higher than enVVeno Medical's net income of -$5.6M. Notably, NeuroOne Medical Technologies's price-to-earnings ratio is -- while enVVeno Medical's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for NeuroOne Medical Technologies is 5.88x versus 213.30x for enVVeno Medical. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income NMTCNeuroOne Medical Technologies5.88x -- $272.3K -$3.4M NVNOenVVeno Medical213.30x -- -- -$5.6M
-
Which has Higher Returns NMTC or SINT?
SINTX Technologies has a net margin of -1230.55% compared to NeuroOne Medical Technologies's net margin of -1700%. NeuroOne Medical Technologies's return on equity of -335.54% beat SINTX Technologies's return on equity of -132.95%.
Company Gross Margin Earnings Per Share Invested Capital NMTCNeuroOne Medical Technologies51.81% -$0.11 $822K SINTSINTX Technologies42.78% -$6.96 $5.7M -
What do Analysts Say About NMTC or SINT?
NeuroOne Medical Technologies has a consensus price target of --, signalling upside risk potential of 163.78%. On the other hand SINTX Technologies has an analysts' consensus of -- which suggests that it could grow by 1888.64%. Given that SINTX Technologies has higher upside potential than NeuroOne Medical Technologies, analysts believe SINTX Technologies is more attractive than NeuroOne Medical Technologies.
Company Buy Ratings Hold Ratings Sell Ratings NMTCNeuroOne Medical Technologies0 0 0 SINTSINTX Technologies0 0 0 -
Is NMTC or SINT More Risky?
NeuroOne Medical Technologies has a beta of 0.688, which suggesting that the stock is 31.224% less volatile than S&P 500. In comparison SINTX Technologies has a beta of 1.497, suggesting its more volatile than the S&P 500 by 49.673%.
-
Which is a Better Dividend Stock NMTC or SINT?
NeuroOne Medical Technologies has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. SINTX Technologies offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. NeuroOne Medical Technologies pays -- of its earnings as a dividend. SINTX Technologies pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios NMTC or SINT?
NeuroOne Medical Technologies quarterly revenues are $272.3K, which are smaller than SINTX Technologies quarterly revenues of $367K. NeuroOne Medical Technologies's net income of -$3.4M is higher than SINTX Technologies's net income of -$6.2M. Notably, NeuroOne Medical Technologies's price-to-earnings ratio is -- while SINTX Technologies's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for NeuroOne Medical Technologies is 5.88x versus 0.96x for SINTX Technologies. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income NMTCNeuroOne Medical Technologies5.88x -- $272.3K -$3.4M SINTSINTX Technologies0.96x -- $367K -$6.2M
-
Which has Higher Returns NMTC or XAIR?
Beyond Air has a net margin of -1230.55% compared to NeuroOne Medical Technologies's net margin of -1673.94%. NeuroOne Medical Technologies's return on equity of -335.54% beat Beyond Air's return on equity of -219.34%.
Company Gross Margin Earnings Per Share Invested Capital NMTCNeuroOne Medical Technologies51.81% -$0.11 $822K XAIRBeyond Air-135.84% -$0.28 $40.5M -
What do Analysts Say About NMTC or XAIR?
NeuroOne Medical Technologies has a consensus price target of --, signalling upside risk potential of 163.78%. On the other hand Beyond Air has an analysts' consensus of -- which suggests that it could grow by 510.5%. Given that Beyond Air has higher upside potential than NeuroOne Medical Technologies, analysts believe Beyond Air is more attractive than NeuroOne Medical Technologies.
Company Buy Ratings Hold Ratings Sell Ratings NMTCNeuroOne Medical Technologies0 0 0 XAIRBeyond Air0 0 0 -
Is NMTC or XAIR More Risky?
NeuroOne Medical Technologies has a beta of 0.688, which suggesting that the stock is 31.224% less volatile than S&P 500. In comparison Beyond Air has a beta of -0.225, suggesting its less volatile than the S&P 500 by 122.529%.
-
Which is a Better Dividend Stock NMTC or XAIR?
NeuroOne Medical Technologies has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Beyond Air offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. NeuroOne Medical Technologies pays -- of its earnings as a dividend. Beyond Air pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios NMTC or XAIR?
NeuroOne Medical Technologies quarterly revenues are $272.3K, which are smaller than Beyond Air quarterly revenues of $798K. NeuroOne Medical Technologies's net income of -$3.4M is higher than Beyond Air's net income of -$13.4M. Notably, NeuroOne Medical Technologies's price-to-earnings ratio is -- while Beyond Air's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for NeuroOne Medical Technologies is 5.88x versus 7.10x for Beyond Air. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income NMTCNeuroOne Medical Technologies5.88x -- $272.3K -$3.4M XAIRBeyond Air7.10x -- $798K -$13.4M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Why Caesars’ Digital Arm May Be the Gaming Giant’s Best-Kept Secret
It’s not often that a company with the scale and…
Will Tyson Foods Stock Bounce Back?
Tyson Foods, Inc. (NYSE:TSN) is one of the biggest food…
Stock Ideas
Buy
64
Is AAPL Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 42x
Buy
52
Is NVDA Stock a Buy?
Market Cap: $3.3T
P/E Ratio: 113x
Buy
55
Is MSFT Stock a Buy?
Market Cap: $3.2T
P/E Ratio: 37x
Alerts
Buy
61
QMCO alert for Dec 23
Quantum [QMCO] is down 0.37% over the past day.
Sell
46
NUKK alert for Dec 23
Nukkleus [NUKK] is up 4.03% over the past day.
Sell
1
IIPR alert for Dec 23
Innovative Industrial Properties [IIPR] is down 5.67% over the past day.
